GlassScriptPhysician profile
Innocent N Odocha
NPI 1568560829
$2,832.56
in general payments reported to CMS, 2019-2025
26 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $333 · 2021: $505 · 2022: $269 · 2023: $326 · 2024: $458 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $433.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $414.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $280.11 | 2019-2022 | |
| Abbott Laboratories | $213.69 | 2019-2024 | Freestyle Libre 3 |
| Pfizer INC. | $202.07 | 2019-2025 | |
| Novo Nordisk INC | $193.06 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $151.63 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $111.86 | 2024-2025 | Otezla, Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $106.04 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $96.23 | 2024 | |
| Exact Sciences Corporation | $95.11 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $91.58 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $87.06 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.70 | 2020-2021 | |
| Astellas Pharma US INC | $48.27 | 2021-2025 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $42.06 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.17 | 2019-2023 | Trulance, Xifaxan |
| Photonicare INC | $24.91 | 2024 | Otosight Middle Ear Scope |
| Dexcom, INC. | $21.85 | 2021 | |
| Ardelyx, INC. | $19.15 | 2025 | Ibsrela |
| Sunovion Pharmaceuticals INC. | $18.71 | 2022 | |
| Esperion Therapeutics, INC. | $18.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.70 | 2019 | |
| Acerus Pharmaceuticals Corporation | $15.11 | 2022 | |
| Insulet Corporation | $14.61 | 2021 | |
| Allergan, INC. | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Innocent Odocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.